Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study
Abstract
Helicobacter pylori infection remains a major global health concern, with rising antibiotic resistance posing significant challenges to eradication efforts. The search for novel, effective regimens is particularly important in regions with high resistance rates to standard agents. This study evaluated the efficacy and safety of nitazoxanide-based quadruple therapies incorporating either levofloxacin or moxifloxacin. In this randomized, multicenter trial, treatment-naïve patients with confirmed H. pylori infection received standard triple therapy with amoxicillin, clarithromycin, and lansoprazole (ACL), levofloxacin-nitazoxanide-doxycycline-lansoprazole (LNDL) or moxifloxacin-nitazoxanide-doxycycline-lansoprazole (MNDL) for 14 days. Eradication was assessed by stool antigen testing. Rates were analyzed using intention-to-treat (ITT) and per-protocol (PP) methods. ITT eradication rates were 82.3% for the LNDL regimen, 71.8% for the MNDL regimen, and only 59.2% for the ACL regimen. Eradication with LNDL was were significantly higher than with ACL. PP analysis showed eradication rates of 87.2% for LNDL and 81.6% for MNDL, both significantly higher than ACL (60.9%). All regimens were well tolerated, with no serious adverse events reported. Fluoroquinolone-containing nitazoxanide-based quadruple regimens demonstrated superior eradication of H. pylori compared to clarithromycin-based triple therapy in treatment-naïve Egyptian patients. Although eradication rates did not reach the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Photochemical behavior of levofloxacin
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Synthesis of [11C]levofloxacin
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.